Do no harm: A critical risk/benefit analysis of child psychotropic medication
Date of Original Version
Prescriptions for psychiatric drugs to children and adolescents skyrocketed in the past ten years. Meanwhile, concerns of suicidality and industry bias in research have prompted regulatory investigation to assess claims that selective serotonin reuptake inhibitors (SSRIs) are safe and effective for children. Family clinicians may be unaware of the controversy or do not have the time or expertise to evaluate drug research. A five flaws analysis of clinical trial research, notably SSRI and stimulant studies, offers an efficient strategy for examining scientific claims. The authors recommend that therapists critically evaluate the scientific basis for medicating youths. Guidelines are provided to assist clinicians helping young people and their families make informed decisions.
Journal of Family Psychotherapy
Sparks, Jacqueline A., and Barry L. Duncan. "Do no harm: A critical risk/benefit analysis of child psychotropic medication." Journal of Family Psychotherapy 19, 1 (2008): 1-19. doi:10.1080/08975350801904072.